Recombinant Human B7-H4 His Tagged Protein, CF

Catalog # Availability Size / Price Qty
6576-B7-050
Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (3)
FAQs
Supplemental Products
Reviews (1)

Recombinant Human B7-H4 His Tagged Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.5‑2.5 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human B7-H4 protein
Phe29-Ala258, with a C-terminal 10-His tag
Accession #
N-terminal Sequence
Analysis
Phe29
Predicted Molecular Mass
26.7 kDa
SDS-PAGE
45-60 kDa, reducing conditions

Product Datasheets

You must select a language.

x

6576-B7

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

6576-B7

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: B7-H4

B7-H4, also known as VTCN1, B7x and B7S1, is a 50 ‑ 80 kDa glycosylated member of the BTN/MOG family of immunomodulatory protein (1, 2). Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3 - 5). Within the ECD, human B7-H4 shares 90% aa sequence identity with mouse and rat B7-H4. It shares 22% - 28% aa sequence identity with human B7-1, B7-2, B7-H1, B7-H2, B7-H3, and PD‑L2. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4 - 8). Following binding to activated T cells, B7-H4 serves as a co‑inhibitor of the T cell response. This is accomplished by reverse signaling that can induce either cell cycle arrest, or apoptosis in B7-H4 expressing cells (3 - 5, 9, 10). B7‑H4 is up‑regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13 - 15). Soluble B7‑H4 functions as a decoy molecule that blocks the inhibitory influence of B7‑H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).

References
  1. Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
  2. Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
  3. Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
  4. Prasad, V.R. et al. (2003) Immunity 18:863.
  5. Sica, G.L. et al. (2003) Immunity 18:849.
  6. Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
  7. Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
  8. Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
  9. Song, H. et al. (2008) Cancer Lett. 266:227.
  10. Park, G.B. et al. (2009) Immunology 128:360.
  11. Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
  12. Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
  13. Simon, I. et al. (2006) Cancer Res. 66:1570.
  14. Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
  15. Azuma, T. et al. (2009) PloS Med. 6:e1000166.
  16. Suh, W.-K. et al. (2006) Mol. Cell. Biol. 26:6403.
Long Name
B7 Homolog 4
Entrez Gene IDs
79679 (Human); 242122 (Mouse); 295322 (Rat)
Alternate Names
B7h.5; B7H4; B7-H4; B7H4T-cell costimulatory molecule B7x; B7S1; B7S1VCTN1; B7x; B7XPRO1291; FLJ22418; Immune costimulatory protein B7-H4; Protein B7S1; T cell costimulatory molecule B7x; V-set domain containing T cell activation inhibitor 1; V-set domain-containing T-cell activation inhibitor 1; Vtcn1

Citations for Recombinant Human B7-H4 His Tagged Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

  1. Impact of the Immunomodulatory Factor Soluble B7-H4 in the Progress of Preeclampsia by Inhibiting Essential Functions of Extravillous Trophoblast Cells
    Authors: Ma, Y;Duan, L;Reisch, B;Kimmig, R;Iannaccone, A;Gellhaus, A;
    Cells
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
    Authors: Toader, D;Fessler, SP;Collins, SD;Conlon, PR;Bollu, R;Catcott, KC;Chin, CN;Dirksen, A;Du, B;Duvall, JR;Higgins, S;Kozytska, MV;Bellovoda, K;Faircloth, C;Lee, D;Li, F;Qin, L;Routhier, C;Shaw, P;Stevenson, CA;Wang, J;Wongthida, P;Ter-Ovanesyan, E;Ditty, E;Bradley, SP;Xu, L;Yin, M;Yurkovetskiy, AV;Mosher, R;Damelin, M;Lowinger, TB;
    Molecular cancer therapeutics
    Species: Human
    Sample Types: Complex Sample Type
    Applications: ELISA Capture
  3. Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4
    Authors: A Garg, R Trout, SA Spector
    Sci Rep, 2017-03-24;7(0):44485.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human B7-H4 His Tagged Protein, CF

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human B7-H4 His Tagged Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human B7-H4 His Tagged Protein, CF
By Anonymous on 09/08/2017
Application: T cell activation Immunoassay
Reason for Rating: We found repeatable results with rhB7H4-his to dampen human T cell activation. We observed inhibition of of HLA-DR and CD45RO upregulation on CD3+ lymphocytes following TCR cross linking and CD28 co-stimulation in the presence of rhB7H4-his.